Most Wall Street analysts recommend buying or holding Moderna (NASDAQ:MRNA) shares. But they don’t necessarily expect big gains in the coming 12 months. The average analyst estimate for that period is about $130 lower than Moderna’s share price today.
It’s…

Click here to view the original article.